A Study of LY3031207 in Healthy Subjects
Study Details
Study Description
Brief Summary
This is a phase I study of LY3031207 in healthy subjects. The purposes of this study are to look at safety, how well the study drug is tolerated, and how much of the study drug gets into the blood stream and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Subjects will participate in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: LY3031207 Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally. |
Drug: LY3031207
Administered orally
|
| Placebo Comparator: Placebo Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose. |
Drug: Placebo
Administered orally
|
| Active Comparator: Celecoxib Single 400mg dose of celecoxib administered orally on one occasion. |
Drug: Celecoxib
Administered orally
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE [Baseline, up to 4 months]
AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.
Secondary Outcome Measures
- Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY3031207 [Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose]
AUC from time 0 to last timepoint (AUC0-tlast) with measurable concentration of LY3031207.
- Pharmacokinetics: Maximum Concentration (Cmax) of LY3031207 [Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose]
- Pharmacodynamics: Percent Change From Baseline of Ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation [Predose, 0.5, 1, 2, 8, 24 and 144 hours post dose.]
The effect of LY3031207 on PGE synthesis in whole blood after ex vivo LPS stimulation.
- Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM) [0 to 2, 2 to 4, 4 to 6, 6 to 12 and 12 to 24 hours post dose]
The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGEM was assessed. PGEM results for each interval were then compared to the baseline value.
- Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM) [0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose]
The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGIM was assessed. PGIM results for each interval were then compared to the baseline value.
- Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM) [0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose]
The participant's urine was collected during protocol-defined intervals and the PGE metabolite TXAM was assessed. TXAM results for each interval were then compared to the baseline value.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male subjects agree to use a reliable method of birth control during the study and for 3 months following the last dose of the investigational product
-
Women not of child-bearing potential due to surgical sterilization (at least 6 weeks after surgical bilateral oophorectomy with or without hysterectomy or at least 6 weeks after tubal ligation) confirmed by medical history or menopause
-
Menopausal women include women with either spontaneous amenorrhea for at least 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (for example [e.g.], oral contraceptives, hormones, gonadotropin-releasing hormone, antiestrogens, selective estrogen receptor modulators, or chemotherapy) or spontaneous amenorrhea for 6 to 12 months and a follicle-stimulating hormone level greater than 40 milli-International Unit (mIU/mL)
-
Overtly healthy based on the history and physical examinations as determined by the investigator
-
Between body mass index (BMI) of 18.5 and 32.0 kilogram per meter squared (kg/m^2), inclusive
-
Normotensive defined as supine systolic blood pressure (BP) <140 of millimeter mercury (mmHg), and diastolic BP <90 mmHg, without the use of any antihypertensives, or results that are judged to be not clinically significant by the Investigator. Blood pressure may be retested up to 2 additional times, under well rested conditions
-
Clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
-
Ex vivo whole blood prostaglandin E(PGE) synthesis after lipopolysaccharide (LPS) stimulation of no less than 5 nanograms/milliliter (ng/mL).
-
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
-
Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
Exclusion Criteria:
-
Are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product or unapproved use of a drug with a short half-life, or within 5 half-life of an investigational product with a half-life longer than 5 days, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
-
Have known allergies to LY3031207 or any components of the formulation, celecoxib or sulfonamides. Subjects with known aspirin allergy or allergic reaction to non-steroidal anti-inflammatory drugs (NSAIDs) should also be excluded
-
Are persons who have previously completed or withdrawn from this study or any other study investigating LY3031207 and who have previously received the investigational product
-
Have an abnormality in the 12-lead Electrocardiogram (ECG), including QTc interval with Bazett's correction >450 millisecond (msec) for men and >470 msec for women or an abnormality that, in the opinion of the investigator, increases the risks associated with participating in the study. Electrocardiogram may be repeated after 5 minutes resting quietly, if the subject's heart rate is >75 beats per minute
-
History of, within the last 2 years, or presence of active cardiovascular disease, including acute myocardial infarction, unstable angina, congestive heart failure, stroke, or transient ischemic attack
-
Presence of clinically significant active bleeding or history of bleeding diathesis at the time of screening
-
Presence of active peptic ulcer disease, Gastrointestinal (GI) bleeding, chronic gastritis, inflammatory bowel disease, chronic diarrhea, or positive H. pylori serology
-
Evidence of hepatitis C and/or positive hepatitis C antibody
-
Evidence of hepatitis B and/or positive hepatitis B surface antigen
-
Evidence of other chronic liver disease, including chronic alcoholic disease; non-alcoholic steatohepatitis; recent (within 3 months of screening) history of acute viral hepatitis; or subjects with known Gilbert Syndrome
-
History of active neuropsychiatric disease
-
Evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies
-
Have a significant history of or current other cardiovascular, respiratory (especially asthma and chronic obstructive pulmonary disease), hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data. History of prior surgeries (at least 3 months prior to dosing), such as splenectomy, cholecystectomy, and appendectomy are not exclusionary
-
Regularly use of known drugs of abuse and/or show positive findings on urinary drug screening
-
Are women with a positive pregnancy test or women who are lactating
-
Intended use of over-the-counter medications or prescription medication within 14 days prior to dosing, this includes but is not limited to antihypertensives, diuretics, antiplatelet or anticoagulant drugs, and antidepressants
-
Any use of NSAIDs, celecoxib, aspirin or acetaminophen (at doses >1 gram [gm] per day) within 14 days of screening
-
Any use of herbal or dietary supplements, or grapefruit and/or grapefruit juice, Seville oranges, starfruit, or pomegranate within 14 days prior to dosing of study drug
-
Have donated blood of more than 500 milliliter (mL) within the last month
-
Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 ounce [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).
-
Subjects who smoke more than 10 cigarettes per day or are unwilling to follow the Clinical Research Unit (CRU) smoking rules
-
Subjects with any major surgery within 30 days prior to screening or subjects with planned surgeries to occur during the study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Evansville | Indiana | United States | 47710 |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 14283
- I5W-EW-LBCA
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail | Three period crossover study with three dosing cohorts. The interval between the initiation of each dosing cohort was approximately 1 week, and the washout time between each dosing period was approximately 3 weeks. |
| Arm/Group Title | Cohort I Sequence 1 | Cohort I Sequence 2 | Cohort I Sequence 3 | Cohort II Sequence 1 | Cohort II Sequence 2 | Cohort II Sequence 3 | Cohort III Sequence 1 | Cohort III Sequence 2 | Cohort III Sequence 3 |
|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 5 mg LY3031207, Placebo and 400 mg Celecoxib as per the below dosing schedule. Period 1: 5 mg LY3031207 , Period 2: Placebo, and Period 3: 400 mg Celecoxib | Participants received 5 mg LY3031207, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule. Period 1: 5 mg LY3031207, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib | Participants received Placebo, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule. Period 1: Placebo, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib | Participants received 25 mg LY3031207 and Placebo as per the below dosing schedule. Period 1: 25 mg LY3031207, Period 2: Placebo and Period 3: Placebo | Participants received 25 mg LY3031207, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule. Period 1: 25 mg LY3031207, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted) | Participants received Placebo, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule. Period 1: Placebo, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted) | Participants received LY3031207 75 mg, Placebo and celecoxib as per the below dosing schedule. Period 1: LY3031207 75 mg, Period 2: Placebo and Period 3: Celecoxib 400 mg | Participants received LY3031207 75 mg, LY3031207 900 mg and celecoxib as per the below dosing schedule. Period 1: LY3031207 75 mg, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg | Participants received Placebo, LY3031207 900 mg and celecoxib as per the below dosing schedule. Period 1: Placebo, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg |
| Period Title: Period 1 | |||||||||
| STARTED | 2 | 6 | 2 | 2 | 5 | 2 | 2 | 6 | 2 |
| Received at Least 1 Dose | 2 | 6 | 2 | 2 | 5 | 1 | 2 | 6 | 2 |
| COMPLETED | 1 | 6 | 2 | 1 | 5 | 1 | 2 | 6 | 2 |
| NOT COMPLETED | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Period Title: Period 1 | |||||||||
| STARTED | 1 | 6 | 2 | 1 | 5 | 1 | 2 | 6 | 2 |
| COMPLETED | 1 | 6 | 2 | 1 | 5 | 1 | 1 | 6 | 2 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Period Title: Period 1 | |||||||||
| STARTED | 1 | 6 | 2 | 1 | 5 | 1 | 1 | 6 | 2 |
| COMPLETED | 1 | 6 | 2 | 1 | 5 | 1 | 1 | 6 | 2 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Cohort I Sequence 1 | Cohort I Sequence 2 | Cohort I Sequence 3 | Cohort II Sequence 1 | Cohort II Sequence 2 | Cohort II Sequence 3 | Cohort III Sequence 1 | Cohort III Sequence 2 | Cohort III Sequence 3 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | Participants received 5 mg LY3031207, Placebo and 400 mg Celecoxib as per the below dosing schedule. Period 1: 5 mg LY3031207 , Period 2: Placebo, and Period 3: 400 mg Celecoxib | Participants received 5 mg LY3031207, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule. Period 1: 5 mg LY3031207, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib | Participants received Placebo, 225 mg LY3031207 and 400 mg Celecoxib as per the below dosing schedule. Period 1: Placebo, Period 2: 225 mg LY3031207 and Period 3: 400 mg Celecoxib | Participants received 25 mg LY3031207 and Placebo as per the below dosing schedule. Period 1: 25 mg LY3031207, Period 2: Placebo and Period 3: Placebo | Participants received 25 mg LY3031207, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule. Period 1: 25 mg LY3031207, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted) | Participants received Placebo, 450 mg LY3031207 (Fed condition) and 450 mg LY3031207 (Fasted) as per the below dosing schedule. Period 1: Placebo, Period 2: 450 mg LY3031207 (Fed) and Period 3: 450 mg LY3031207 (Fasted) | Participants received LY3031207 75 mg, Placebo and celecoxib as per the below dosing schedule. Period 1: LY3031207 75 mg, Period 2: Placebo and Period 3: Celecoxib 400 mg | Participants received LY3031207 75 mg, LY3031207 900 mg and celecoxib as per the below dosing schedule. Period 1: LY3031207 75 mg, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg | Participants received Placebo, LY3031207 900 mg and celecoxib as per the below dosing schedule. Period 1: Placebo, Period 2: LY3031207 900 mg and Period 3: Celecoxib 400 mg | Total of all reporting groups |
| Overall Participants | 2 | 6 | 2 | 2 | 5 | 2 | 2 | 6 | 2 | 29 |
| Age (Count of Participants) | ||||||||||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
2
100%
|
6
100%
|
2
100%
|
2
100%
|
5
100%
|
2
100%
|
2
100%
|
6
100%
|
2
100%
|
29
100%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Sex: Female, Male (Count of Participants) | ||||||||||
| Female |
1
50%
|
3
50%
|
1
50%
|
0
0%
|
1
20%
|
1
50%
|
1
50%
|
1
16.7%
|
0
0%
|
9
31%
|
| Male |
1
50%
|
3
50%
|
1
50%
|
2
100%
|
4
80%
|
1
50%
|
1
50%
|
5
83.3%
|
2
100%
|
20
69%
|
| Race/Ethnicity, Customized (Count of Participants) | ||||||||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
20%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
3.4%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
1
50%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
1
50%
|
2
6.9%
|
| White |
1
50%
|
6
100%
|
2
100%
|
2
100%
|
4
80%
|
2
100%
|
2
100%
|
6
100%
|
1
50%
|
26
89.7%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Region of Enrollment (Count of Participants) | ||||||||||
| United States |
2
100%
|
6
100%
|
2
100%
|
2
100%
|
5
100%
|
2
100%
|
2
100%
|
6
100%
|
2
100%
|
29
100%
|
Outcome Measures
| Title | Number of Participants With 1 or More Drug Related Adverse Events (AE) or Any Serious AE |
|---|---|
| Description | AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module. |
| Time Frame | Baseline, up to 4 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received at least 1 dose of study drug or placebo. |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib |
|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 milligrams (mg) LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. | Matched placebo capsules administered orally. | 400 mg Celecoxib administered orally as capsules. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 | 10 | 18 |
| Serious AEs |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Other Non-Serious AEs |
3
150%
|
3
50%
|
1
50%
|
1
50%
|
0
0%
|
2
100%
|
2
100%
|
2
33.3%
|
1
50%
|
| Title | Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of LY3031207 |
|---|---|
| Description | AUC from time 0 to last timepoint (AUC0-tlast) with measurable concentration of LY3031207. |
| Time Frame | Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Pharmacokinetic (PK) population: All participants who received at least 1 dose of study drug and had evaluable PK data. |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 |
| Geometric Mean (Geometric Coefficient of Variation) [nanogram*hour per milliliter (ng*hr/mL)] |
3040
(31)
|
13900
(65)
|
40000
(32)
|
151000
(28)
|
171000
(54)
|
116000
(73)
|
348000
(63)
|
| Title | Pharmacokinetics: Maximum Concentration (Cmax) of LY3031207 |
|---|---|
| Description | |
| Time Frame | Predose, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 96, 144 hours post dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Pharmacokinetic (PK) population: all participants who received at least one dose of study drug and had evaluable PK data. |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 |
|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 |
| Geometric Mean (Geometric Coefficient of Variation) [nanograms per milliliter (ng/mL)] |
185
(35)
|
818
(40)
|
2060
(20)
|
5610
(31)
|
7780
(32)
|
5670
(49)
|
11300
(45)
|
| Title | Pharmacodynamics: Percent Change From Baseline of Ex Vivo Whole Blood Prostaglandin E (PGE) Synthesis After Lipopolysaccharide (LPS) Stimulation |
|---|---|
| Description | The effect of LY3031207 on PGE synthesis in whole blood after ex vivo LPS stimulation. |
| Time Frame | Predose, 0.5, 1, 2, 8, 24 and 144 hours post dose. |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received at least 1 dose of study drug or placebo with evaluable PGE data at the specific time points. |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib |
|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. | Matched placebo capsules administered orally. | 400 mg Celecoxib administered orally as capsules. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 | 11 | 18 |
| 0.5 hours (hr) |
-16.2
(32.9)
|
-15.6
(26.4)
|
33.0
(45.0)
|
12.7
(64.0)
|
42.7
(69.7)
|
-85.1
(13.8)
|
-43.1
(17.8)
|
56.1
(97.9)
|
-10.4
(77.6)
|
| 1 hr |
-9.2
(43.5)
|
-4.8
(67.7)
|
24.6
(67.5)
|
-16.8
(93.7)
|
-83.8
(41.4)
|
-92.9
(8.5)
|
-93.7
(6.9)
|
65.4
(116.8)
|
-44.8
(59.5)
|
| 2 hr |
-34.3
(20.1)
|
-45.5
(49.4)
|
-47.0
(19.8)
|
-79.2
(21.2)
|
-104.9
(11.8)
|
-96.4
(8.9)
|
-83.3
(11.8)
|
65.1
(106.6)
|
-68.2
(27.8)
|
| 8 hr |
-8.5
(41.0)
|
-40.1
(25.4)
|
-41.3
(35.9)
|
-79.3
(6.6)
|
-94.3
(13.9)
|
-88.3
(13.5)
|
-98.4
(3.8)
|
76.9
(109.1)
|
-63.1
(32.1)
|
| 24 hr |
89.4
(153.9)
|
8.7
(73.3)
|
60.0
(84.3)
|
-29.5
(NA)
|
-76.8
(40.6)
|
-54.1
(28.4)
|
-88.8
(12.2)
|
124.8
(139.3)
|
-19.9
(60.7)
|
| 144 hr |
178.2
(96.5)
|
24.3
(58.2)
|
153.7
(70.9)
|
131.1
(111.4)
|
125.1
(104.6)
|
48.0
(49.3)
|
41.4
(101.1)
|
159.1
(138.7)
|
7.6
(76.5)
|
| Title | Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostaglandin E(2) Metabolite (PGEM) |
|---|---|
| Description | The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGEM was assessed. PGEM results for each interval were then compared to the baseline value. |
| Time Frame | 0 to 2, 2 to 4, 4 to 6, 6 to 12 and 12 to 24 hours post dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received at least 1 dose of study drug or placebo with evaluable PGEM data at specific time points. |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib |
|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. | Matched placebo capsules administered orally. | 400 mg Celecoxib administered orally as capsules. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 | 11 | 18 |
| 0 - 2 hr interval |
14.4
(35.8)
|
18.5
(31.4)
|
11.0
(40.6)
|
-26.6
(25.9)
|
17.3
(53.5)
|
10.7
(32.7)
|
-19.8
(36.4)
|
5.8
(47.3)
|
-14.6
(40.7)
|
| 2 - 4 hr interval |
14.5
(39.4)
|
-2.1
(43.4)
|
5.8
(45.5)
|
-45.2
(32.3)
|
6.1
(66.3)
|
29.6
(64.1)
|
-12.0
(41.4)
|
11.2
(32.1)
|
-30.7
(36.1)
|
| 4 - 6 hr interval |
-0.8
(39.3)
|
-1.5
(57.4)
|
-22.1
(35.5)
|
-44.2
(27.3)
|
-9.2
(56.9)
|
15.8
(50.8)
|
-24.2
(39.4)
|
6.3
(44.4)
|
-32.3
(42.4)
|
| 6 - 12 hr interval |
4.9
(40.9)
|
-17.9
(56.4)
|
-13.5
(42.5)
|
-41.9
(23.7)
|
-18.8
(42.5)
|
-13.0
(38.0)
|
-37.5
(26.2)
|
2.9
(44.0)
|
-36.8
(27.9)
|
| 12 - 24 hr interval |
3.9
(20.1)
|
-32.6
(33.5)
|
-12.9
(31.0)
|
-37.9
(29.3)
|
-26.9
(43.6)
|
-7.3
(38.2)
|
-43.6
(33.1)
|
0.9
(32.8)
|
-46.5
(17.8)
|
| Title | Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Prostacyclin Metabolite (PGIM) |
|---|---|
| Description | The participant's urine was collected during protocol-defined intervals and the PGE metabolite PGIM was assessed. PGIM results for each interval were then compared to the baseline value. |
| Time Frame | 0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received at least 1 dose of study drug or placebo with evaluable PGIM data at specific time points |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib |
|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 of LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. | Matched placebo capsules administered orally. | 400 mg Celecoxib administered orally as capsules. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 | 11 | 18 |
| At 0 - 2 hr interval |
14.1
(36.5)
|
25.2
(41.9)
|
-3.9
(27.4)
|
11.7
(28.0)
|
44.6
(44.3)
|
137.2
(195.5)
|
37.2
(30.1)
|
-17.0
(24.2)
|
-18.9
(25.6)
|
| At 2 - 4 hr interval |
34.0
(64.3)
|
30.5
(20.8)
|
21.2
(35.4)
|
33.1
(42.8)
|
244.7
(147.6)
|
174.1
(249.0)
|
122.5
(114.3)
|
6.2
(81.9)
|
-44.6
(21.3)
|
| At 4 - 6 hr interval |
73.8
(66.1)
|
19.3
(45.8)
|
31.0
(52.0)
|
72.1
(69.3)
|
198.3
(80.0)
|
186.7
(70.1)
|
264.0
(114.3)
|
28.3
(71.1)
|
-25.6
(45.4)
|
| At 6 - 12 hr interval |
48.0
(45.1)
|
52.1
(45.2)
|
63.6
(19.1)
|
71.7
(66.4)
|
208.5
(78.8)
|
190.0
(117.5)
|
201.4
(141.9)
|
57.5
(208.1)
|
-12.1
(53.8)
|
| Title | Pharmacodynamics: Percent Change From Baseline of Urinary Excretion of Thromboxane A Metabolite (TXAM) |
|---|---|
| Description | The participant's urine was collected during protocol-defined intervals and the PGE metabolite TXAM was assessed. TXAM results for each interval were then compared to the baseline value. |
| Time Frame | 0 to 2, 2 to 4, 4 to 6, and 6 to 12 hours post dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| All participants who received at least 1 dose of study drug or placebo with evaluable TXAM data at specific time points. |
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib |
|---|---|---|---|---|---|---|---|---|---|
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted. | 900 mg LY3031207 administered orally as capsules as a single dose. | Matched placebo capsules administered orally. | 400 mg Celecoxib administered orally as capsules. |
| Measure Participants | 8 | 6 | 8 | 7 | 6 | 6 | 8 | 11 | 18 |
| At 0 - 2 hr interval |
-9.0
(10.2)
|
-5.7
(9.6)
|
0.9
(17.4)
|
-11.3
(10.8)
|
4.4
(13.8)
|
25.2
(31.5)
|
11.0
(24.7)
|
-11.5
(22.6)
|
-6.2
(19.3)
|
| At 2 - 4 hr interval |
4.1
(16.1)
|
-15.5
(7.7)
|
19.7
(23.7)
|
0.7
(22.1)
|
40.4
(52.4)
|
28.3
(58.3)
|
106.2
(107.1)
|
-17.4
(17.2)
|
-25.4
(17.0)
|
| At 4 - 6 hr interval |
1.3
(25.4)
|
-16.5
(11.4)
|
1.2
(16.9)
|
-3.8
(16.4)
|
29.4
(29.6)
|
16.7
(25.2)
|
88.5
(47.9)
|
-18.3
(18.7)
|
-33.3
(10.6)
|
| At 6 - 12 hr interval |
6.8
(29.5)
|
-15.7
(19.6)
|
20.7
(23.2)
|
8.0
(25.2)
|
30.9
(29.6)
|
9.0
(23.1)
|
85.8
(85.9)
|
13.1
(14.8)
|
-19.8
(18.3)
|
Adverse Events
| Time Frame | Up To 4 Months | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||||||||||||
| Arm/Group Title | 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib | |||||||||
| Arm/Group Description | 5 mg LY3031207 administered orally as capsules as a single dose. | 25 mg LY3031207 administered orally as capsules as a single dose. | 75 mg LY3031207 administered orally as capsules as a single dose. | 225 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose. | 450 mg LY3031207 administered orally as capsules as a single dose to participants who were fasted before receiving drug. | 900 mg LY3031207 administered orally as capsules as a single dose. | Matched placebo capsules administered orally. | 400 mg Celecoxib administered orally as capsules. | |||||||||
All Cause Mortality |
||||||||||||||||||
| 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib | ||||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | / (NaN) | |||||||||
Serious Adverse Events |
||||||||||||||||||
| 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib | ||||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/8 (0%) | 0/6 (0%) | 0/8 (0%) | 0/7 (0%) | 0/6 (0%) | 0/6 (0%) | 0/8 (0%) | 0/10 (0%) | 0/18 (0%) | |||||||||
Other (Not Including Serious) Adverse Events |
||||||||||||||||||
| 5 mg LY3031207 | 25 mg LY3031207 | 75 mg LY3031207 | 225 mg LY3031207 | 450 mg LY3031207 Fed | 450 mg LY3031207 Fasted | 900 mg LY3031207 | Placebo | 400 mg Celecoxib | ||||||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/8 (37.5%) | 3/6 (50%) | 1/8 (12.5%) | 1/7 (14.3%) | 0/6 (0%) | 2/6 (33.3%) | 2/8 (25%) | 2/10 (20%) | 1/18 (5.6%) | |||||||||
| Blood and lymphatic system disorders | ||||||||||||||||||
| Anaemia | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Eye disorders | ||||||||||||||||||
| Photophobia | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Visual impairment | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Gastrointestinal disorders | ||||||||||||||||||
| Abdominal distension | 1/8 (12.5%) | 1 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Nausea | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Toothache | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 1/10 (10%) | 1 | 0/18 (0%) | 0 |
| General disorders | ||||||||||||||||||
| Fatigue | 1/8 (12.5%) | 1 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Vessel puncture site haematoma | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 1/10 (10%) | 1 | 0/18 (0%) | 0 |
| Infections and infestations | ||||||||||||||||||
| Gingival infection | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 1/10 (10%) | 1 | 0/18 (0%) | 0 |
| Viral upper respiratory tract infection | 1/8 (12.5%) | 1 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Injury, poisoning and procedural complications | ||||||||||||||||||
| Concussion | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Investigations | ||||||||||||||||||
| Weight increased | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 1/8 (12.5%) | 1 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||||||||||||||||
| Back pain | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Neck pain | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 1/10 (10%) | 1 | 0/18 (0%) | 0 |
| Nervous system disorders | ||||||||||||||||||
| Dizziness | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 1/7 (14.3%) | 1 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Headache | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 1/8 (12.5%) | 1 | 0/10 (0%) | 0 | 1/18 (5.6%) | 1 |
| Loss of consciousness | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Tremor | 0/8 (0%) | 0 | 1/6 (16.7%) | 1 | 0/8 (0%) | 0 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
| Reproductive system and breast disorders | ||||||||||||||||||
| Testicular pain | 0/8 (0%) | 0 | 0/6 (0%) | 0 | 1/8 (12.5%) | 1 | 0/7 (0%) | 0 | 0/6 (0%) | 0 | 0/6 (0%) | 0 | 0/8 (0%) | 0 | 0/10 (0%) | 0 | 0/18 (0%) | 0 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Chief Medical Officer |
|---|---|
| Organization | Eli Lilly and Company |
| Phone | 800-545-5979 |
- 14283
- I5W-EW-LBCA